Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary NanoString to Present at the 2018 UBS Global Health Care Conference
SEATTLE , May 15, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the 2018 UBS Global Heath Care Conference
View HTML
Toggle Summary NanoString Technologies Releases Operating Results for First Quarter of 2018
SEATTLE , May 08, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the first quarter of 2018. First Quarter Financial Highlights Total revenue of
View HTML
Toggle Summary NanoString to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
SEATTLE , May 02, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the Bank of America Merrill Lynch 2018
View HTML
Toggle Summary NanoString Partners with Multiple Leading Contract Research Organizations to Market Digital Spatial Profiling Service
Expanded Technology Access Program Responds to Interest from Leading Biopharmaceutical Companies and Lab Service Providers SEATTLE , April 30, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic
View HTML
Toggle Summary NanoString Showcases Groundbreaking Body of Research at the 2018 Annual Meeting of the American Association for Cancer Research
More than 50 abstracts highlight the diverse capabilities of NanoString’s technology from gene expression profiling to Digital Spatial Profiling SEATTLE , April 12, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and
View HTML
Toggle Summary NanoString Announces Launch of Breast Cancer 360 Research Panel, Expanding the 360 Series of Cancer Panels for Translational Research and Signature Development
SEATTLE , April 10, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the launch of the Breast Cancer 360™ (BC 360) research panel.
View HTML
Toggle Summary NanoString to Release First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018
SEATTLE , April 09, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2018 financial results after the close of trading on
View HTML
Toggle Summary NanoString Technologies Releases Fourth Quarter and Full Year 2017 Operating Results and Provides 2018 Outlook
SEATTLE , March 07, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the fourth quarter and year ended December 31, 2017.
View HTML
Toggle Summary NanoString to Present at the 38th Annual Cowen Healthcare Conference
SEATTLE , March 06, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the 38th Annual Cowen Healthcare
View HTML
Toggle Summary NanoString Technologies to Release Fourth Quarter and Fiscal Year 2017 Financial Results and Host Conference Call on Wednesday, March 7, 2018
SEATTLE , Feb. 21, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release fourth quarter and fiscal year 2017 financial results after the close
View HTML